New trial shows immunotherapy post-surgery improves overall survival for kidney cancer

by

For the first time in fifty years, results from a Phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *